Released Nov 5, 2020, before the open
10-Q filed Nov 5, 2020, 36 days after period end · 0001564590-20-050898
Q3 2020 · 10-Q
Revenue$110.99M$110.99M −2.2% vs Q3 2019+51.8% vs Q2 2020
Net Income$4.65M$4.65M N/M vs Q3 2019N/M vs Q2 2020
EPS Diluted$0.24$0.24 N/M vs Q3 2019N/M vs Q2 2020
Gross Profit$84,742,000−4.4%
Operating Income$4,175,000N/M
Operating Cash Flowderived$21,887,000+86.3%
Free Cash Flowderived$18,822,000+147.5%
Margins · derived
Gross margin76.4%−1.7 pt vs Q3 2019
Operating margin3.8%+20.4 pt vs Q3 2019
Net margin4.2%+39.9 pt vs Q3 2019
What the release said
The release
Same quarter
| Metric | Q3 2020 | Q3 2019 | Q3 2018 | Q3 2017 |
|---|---|---|---|---|
| Revenue | $110.99M | $113.50M | $111.71M | $105.25M |
| Net Income | $4.65M | -$40.50M | -$1.21M | $3.46M |
| EPS Diluted | $0.24 | -$2.14 | -$0.07 | $0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR